“A diagnostic center of Cordlife sciences to provide different types of diagnostics to the mother and child”

January 31, 2019 – Kolkata, India - Cordlife Sciences India Pvt. Ltd. launched, a new division Cordlife Diagnostics in association with Sandor Speciality Diagnostics. Cordlife Group Limited is a consumer healthcare company, established in May 2001, catering a healthy life to both mother and child. Cordlife is the oldest and largest network of cord blood banks in South East Asia. Headquartered in Kolkata, Cordlife Sciences India Pvt. Ltd. is a subsidiary of Cordlife Group Limited, a Singapore Exchange (“SGX”) Main Board listed company. Cordlife has expanded its operations to over 210 cities in India. The Indian Laboratory is AABB accredited with a storage capacity of 150,000 cord blood units scalable by another few lakh units. The laboratory is equipped with the latest and the most modern equipment such as Swiss-made SEPAX® 2, a fully automated stem cell processing technology. Our emphasis is to always remain at the forefront of science by adapting and offering the best advancements in processing and cryopreservation technologies to our clients.

So, Cordlife diagnostics is now spreading its horizons into the diagnostics and biomedical services in association with Sandor Lifesciences. Sandor Lifesciences, the state-of-the-art laboratory, was established in 2007 to focus on the development of biomarkers and molecular diagnostics leading to personalized medicine. The significant goal of Sandor Lifesciences is to produce authenticated biomarkers that can be used for doing diagnostic assays. This will help in the categorization of medicine. With its high-end laboratory and logistics capabilities, Sandor has become a major resource base for a variety of scientific research in India. In addition, Sandor solves the regulatory challenges for pharmaceutical and diagnostic companies by providing consulting services and turnkey solutions in the areas of clinical research.

Cordlife diagnostics division provides Genscreen® and Metascreen™ test.

Genscreen® specializes in providing advanced Non-Invasive Prenatal Testing (NIPT) capabilities from qualified healthcare partners around the world to mothers-to-be in Indonesia, Philippines, and Singapore. The tests are performed as early as 10 weeks into pregnancy and employ Whole Genome Sequencing high-quality medical reporting protocol. It also helps to significantly reduce the need for unnecessary and risky invasive testing to identify the possible presence of genetic diseases or gene mutations associated with increased risk of developing certain medical conditions.

Metascreen™ is a marketing trademark of Cordlife Group Limited, a Singapore Exchange Mainboard-listed company. It is a newborn metabolic screening test offered by Cordlife in Hong Kong, India, Indonesia, Malaysia, Myanmar, Philippines, Singapore, and Vietnam. The screening test offered under the brand is conducted by Hong Kong Screening Centre, a company committed to providing early and accurate detection of metabolic disorders in newborn babies.

The goal of cordlife diagnostic is to apply advanced technology so that they can meet the challenges of treatment by early diagnosis of the diseases. Hence the Cordlife Division promises to deliver the best diagnosis of the pregnant lady as well as the newborn child in a proper way which is convenient for both the patient and the clinician.